Lundbeck kept at neutral by Merrill

Lundbeck was retained at its neutral rating by Merrill Lynch analyst Erica Whittaker after the company beat Merrill's first-quarter top line forecasts thanks to antidepressant revenues. But the company missed on the bottom line, causing Merrill to forecast negative net financial income for the year, lowering its net income estimate to DKr990 million from DKr1.1 billion. Shares of the Melville, N.Y., pharmaceutical company were up DKr5.25 at DKr140.75. (Copenhagen: LUN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.